Rapo

Indication:

Healing of erosive or ulcerative gastro-esophageal reflux disease; Maintenance of healing of erosive or ulcerative gastro-esophageal reflux disease; Benign gastric ulcer; Healing of duodenal ulcer; Treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.

 

Dosage & Administration:

Healing of erosive or ulcerative gastroesophageal reflux disease (GERD): 20 mg once daily in the morning for 4-8 weeks. For those patients who have not been healed after 8 weeks of treatment, an additional 8-week course may be considered. Maintenance of healing of erosive or ulcerative gastroesophageal reflux disease: 20 mg once daily in the morning. Benign gastric ulcer: 20 mg once daily in the morning for 6 weeks, followed by a further 6 weeks if not fully healed.

Healing of duodenal ulcer: 20 mg once daily in the morning for a period upto 4 weeks. A few patients may require additional therapy to achieve healing. Pathological hypersecretory conditions including Zollinger-Ellison Syndrome: The recommended adult oral starting dose is 60 mg daily. Doses should be adjusted to individual patient needs and should be continued as long as clinically indicated. Some patients may require divided doses. 

Preparation:

Rapo-20 mg Tablet: Each enteric-coated tablet contains Rabeprazole Sodium INN 20 mg.